OTCPK:VPRO

Stock Analysis Report

Executive Summary

Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases.


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.

Share Price & News

How has Viropro's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: VPRO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-11.2%

VPRO

0.7%

US Biotechs

-1.1%

US Market


1 Year Return

-21.8%

VPRO

14.0%

US Biotechs

17.9%

US Market

Return vs Industry: VPRO underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: VPRO underperformed the US Market which returned 17.9% over the past year.


Shareholder returns

VPROIndustryMarket
7 Day-11.2%0.7%-1.1%
30 Day-26.9%5.6%1.4%
90 Day55.4%6.2%6.9%
1 Year-21.8%-21.8%14.9%14.0%20.3%17.9%
3 Year-56.7%-56.7%24.4%21.1%47.8%38.3%
5 Year13.0%13.0%3.8%-1.0%71.9%53.0%

Price Volatility Vs. Market

How volatile is Viropro's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Viropro undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Viropro is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Viropro has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of VPRO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Viropro regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Viropro forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

20.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Viropro has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Viropro performed over the past 5 years?

23.7%

Historical Pharmaceuticals & Biotech annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Viropro has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Viropro's financial position?


In this section we usually analyse Viropro's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Viropro has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of VPRO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Viropro's financial data was last updated here.
  • Explore more healthy companies in the Pharmaceuticals & Biotech industry.

Dividend

What is Viropro's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate VPRO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VPRO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VPRO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VPRO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VPRO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.0yrs

Average board tenure


CEO

Viropro has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Bruce Cohen
Chairman & Treasurer0yrsno datano data
Michelle Leanne Peake
Secretary & Director7.3yrsno datano data
Ivor Royston
Director4.2yrsno datano data
Howard Levine
Member of Scientific Advisory Board8.8yrsno datano data
Pete Fernandes
Member of Scientific Advisory Board8.8yrsno datano data

8.0yrs

Average Tenure

Experienced Board: VPRO's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Top Shareholders

Company Information

Viropro Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Viropro Inc.
  • Ticker: VPRO
  • Exchange: OTCPK
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.579m
  • Shares outstanding: 1.27b
  • Website: https://www.viropro.net

Location

  • Viropro Inc.
  • 2151 O'Toole Avenue
  • Suite 50
  • San Jose
  • California
  • 95131
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VPROOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJul 2011

Biography

Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic proteins for the treatment of various diseases. The company is also involved in the transfer of its proprietary technologies for industrial production of biogeneric therapeutic proteins for the treatment of various diseases, such as cancer, diabetes, hepatitis, or multiple sclerosis. It manufactures biologics drugs, including bio-similars for pre-clinical, and Phase I, II, and III clinical trials; offers its clients with supply of mammalian cell proteins, such as monoclonal antibodies or recombinant proteins, or other cell-derived products; owns three clones that include two in insulin therapy and one for cancer therapy; and provides contractual research and manufacturing services to biotech and biopharmaceutical companies. The company’s contractual work activities include cloning, sequencing, purifying, developing, validating, and producing biopharmaceutical products and sub-products. It has operations in Canada, the United Kingdom, and Malaysia. Viropro Inc. has collaboration agreement with Oncobiologics, Inc. to manufacture and commercialize monoclonal antibody products. The company is based in San Jose, California. Viropro Inc. is a subsidiary of Alpha Biologics Limited. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 01:50
End of Day Share Price2020/02/21 00:00
EarningsN/A
Annual EarningsN/A


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.